Several studies suggest that a fibroblast‐derived niche can offer the therapeutic escape of melanoma cells from BRAF inhibition.[2, 23] Reports also suggest that the BRAF inhibitor itself plays a critical role in activating fibroblasts in the tumor tissue. This evidence concerns the gene BRAF and melanoma.